# Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)

Study · id `cardio:ct-nct02291874` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02291874](<https://clinicaltrials.gov/study/NCT02291874>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02291874

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02291874. Allocation not applicable; no masking; primary purpose treatment. Start 2014-10-08 (actual); primary completion 2016-07-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02291874, source copy `cardio:ctgov-nct02291874-2024-11-08`, retrieved 2026-10-26)
- Started: 2014-10-08 (actual) (ClinicalTrials.gov record NCT02291874, source copy `cardio:ctgov-nct02291874-2024-11-08`, retrieved 2026-10-26)
- Primary completion: 2016-07-07 (actual) (ClinicalTrials.gov record NCT02291874, source copy `cardio:ctgov-nct02291874-2024-11-08`, retrieved 2026-10-26)
- Completion: 2016-07-07 (actual) (ClinicalTrials.gov record NCT02291874, source copy `cardio:ctgov-nct02291874-2024-11-08`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02291874, source copy `cardio:ctgov-nct02291874-2024-11-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02291874-2024-11-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ipragliflozin
- Lead sponsor: Astellas Pharma Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: c3f1d0fe51d9bf6eaa3397c57d250c95295f1ac8c8ac35d01c4521249804e342
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
